Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB

Detalles Bibliográficos
Autores principales: Chalkidou, Kalipso, Towse, Adrian, Silverman, Rachel, Garau, Martina, Ramakrishnan, Ganesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204919/
https://www.ncbi.nlm.nih.gov/pubmed/32332035
http://dx.doi.org/10.1136/bmjgh-2019-002061
_version_ 1783530146834153472
author Chalkidou, Kalipso
Towse, Adrian
Silverman, Rachel
Garau, Martina
Ramakrishnan, Ganesh
author_facet Chalkidou, Kalipso
Towse, Adrian
Silverman, Rachel
Garau, Martina
Ramakrishnan, Ganesh
author_sort Chalkidou, Kalipso
collection PubMed
description
format Online
Article
Text
id pubmed-7204919
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-72049192020-05-12 Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB Chalkidou, Kalipso Towse, Adrian Silverman, Rachel Garau, Martina Ramakrishnan, Ganesh BMJ Glob Health Commentary BMJ Publishing Group 2020-04-23 /pmc/articles/PMC7204919/ /pubmed/32332035 http://dx.doi.org/10.1136/bmjgh-2019-002061 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Commentary
Chalkidou, Kalipso
Towse, Adrian
Silverman, Rachel
Garau, Martina
Ramakrishnan, Ganesh
Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
title Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
title_full Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
title_fullStr Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
title_full_unstemmed Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
title_short Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
title_sort market-driven, value-based, advance commitment (mvac): accelerating the development of a pathbreaking universal drug regimen to end tb
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204919/
https://www.ncbi.nlm.nih.gov/pubmed/32332035
http://dx.doi.org/10.1136/bmjgh-2019-002061
work_keys_str_mv AT chalkidoukalipso marketdrivenvaluebasedadvancecommitmentmvacacceleratingthedevelopmentofapathbreakinguniversaldrugregimentoendtb
AT towseadrian marketdrivenvaluebasedadvancecommitmentmvacacceleratingthedevelopmentofapathbreakinguniversaldrugregimentoendtb
AT silvermanrachel marketdrivenvaluebasedadvancecommitmentmvacacceleratingthedevelopmentofapathbreakinguniversaldrugregimentoendtb
AT garaumartina marketdrivenvaluebasedadvancecommitmentmvacacceleratingthedevelopmentofapathbreakinguniversaldrugregimentoendtb
AT ramakrishnanganesh marketdrivenvaluebasedadvancecommitmentmvacacceleratingthedevelopmentofapathbreakinguniversaldrugregimentoendtb

Ejemplares similares